loading

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

pulisher
Apr 24, 2025

Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Nasdaq

Apr 24, 2025
pulisher
Apr 22, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | RARE Stock News - GuruFocus

Apr 22, 2025
pulisher
Apr 22, 2025

Ultragenyx Expands Team with 21 New Hires, Grants Nearly 37,000 Restricted Stock Units - Stock Titan

Apr 22, 2025
pulisher
Apr 22, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Apr 22, 2025
pulisher
Apr 21, 2025

BofA Adjusts Price Target for Ultragenyx (RARE) Ahead of Q1 Earnings | RARE Stock News - GuruFocus

Apr 21, 2025
pulisher
Apr 20, 2025

Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hypophosphatemia in Children | Libero Quotidiano.it - Libero Quotidiano

Apr 20, 2025
pulisher
Apr 18, 2025

Mucopolysaccharidosis (MPS) Treatment Market Generated - openPR.com

Apr 18, 2025
pulisher
Apr 17, 2025

How did Emil Kakkis build Ultragenyx into an ultrarare-disease powerhouse? - The Business Journals

Apr 17, 2025
pulisher
Apr 17, 2025

BofA Adjusts Price Target on Ultragenyx Pharmaceutical to $80 From $83, Keeps Buy Rating - marketscreener.com

Apr 17, 2025
pulisher
Apr 16, 2025

Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline (NASDAQ:RARE) - Seeking Alpha

Apr 16, 2025
pulisher
Apr 15, 2025

Roche's castoff Angelman drug gets second life in Oak Hill deal - FirstWord Pharma

Apr 15, 2025
pulisher
Apr 13, 2025

Ultragenyx Pharmaceutical (RARE): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential - MSN

Apr 13, 2025
pulisher
Apr 10, 2025

Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock? - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

X-linked Hypophosphatemia Market Future Business - openPR.com

Apr 10, 2025
pulisher
Apr 07, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Is Carrying A Fair Bit Of Debt - simplywall.st

Apr 07, 2025
pulisher
Apr 05, 2025

Ultragenyx stock hits 52-week low at $33.37 amid market challenges - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

Ultragenyx stock hits 52-week low at $33.37 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 02, 2025

How another firm's FDA approval could mean a big win for Denali TherapeuticsSan Francisco Business Times - The Business Journals

Apr 02, 2025
pulisher
Apr 02, 2025

Winners and wishers: 9 potential Bay Area drug approvals coming this yearSan Francisco Business Times - The Business Journals

Apr 02, 2025
pulisher
Apr 02, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 52-Week LowShould You Sell? - MarketBeat

Apr 02, 2025
pulisher
Mar 30, 2025

11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey

Mar 30, 2025
pulisher
Mar 29, 2025

Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey

Mar 29, 2025
pulisher
Mar 27, 2025

Ultragenyx Stays On JPMorgan's Focus List As Analyst Highlights Strong Long-Term Positioning - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Ultragenyx price target raised to $117 from $104 at JPMorgan - TipRanks

Mar 27, 2025
pulisher
Mar 26, 2025

Ultragenyx stock hits 52-week low at $36.99 amid market challenges - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

Ultragenyx stock hits 52-week low at $36.99 amid market challenges By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Strategic Move: Ultragenyx CCO Erik Harris to Drive Rezolute's Rare Disease Commercialization - Stock Titan

Mar 26, 2025
pulisher
Mar 24, 2025

Ultragenyx CEO Emil Kakkis: ‘Our Future Is In Our Hands’ - insights.citeline.com

Mar 24, 2025
pulisher
Mar 24, 2025

Can UX111 Script History As The First FDA-Approved Treatment For Sanfilippo Syndrome Type A? - RTTNews

Mar 24, 2025
pulisher
Mar 19, 2025

Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

Ultragenyx Strengthens Team with Strategic RSU Grants Worth Millions - StockTitan

Mar 19, 2025
pulisher
Mar 18, 2025

Ultragenyx price target lowered to $115 from $140 at Piper Sandler - Yahoo Finance

Mar 18, 2025
pulisher
Mar 17, 2025

Piper Sandler cuts Ultragenyx stock target to $115; keeps overweight By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

Demystifying Ultragenyx Pharmaceutical: Insights From 10 Analyst Reviews - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

Piper Sandler cuts Ultragenyx stock target to $115; keeps overweight - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Opinion: Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx and Neuren - BioSpace

Mar 17, 2025
pulisher
Mar 12, 2025

Trending Report on X-linked Hypophosphatemia Market 2025-2032 - openPR

Mar 12, 2025
pulisher
Mar 11, 2025

Have Insiders Sold Ultragenyx Pharmaceutical Shares Recently? - Simply Wall St

Mar 11, 2025
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Kapitalisierung:     |  Volumen (24h):